{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:45:22Z","timestamp":1782301522744,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-29276-9","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T09:27:17Z","timestamp":1764322037000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment outcomes of sunitinib and\/or pazopanib in advanced alveolar soft part sarcoma: A Turkish Oncology Group (TOG) study"],"prefix":"10.1038","volume":"15","author":[{"given":"Zehra Sucuo\u011flu","family":"\u0130\u015fleyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seval","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ertu\u011frul","family":"Bayram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eaban","family":"Se\u00e7meler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O\u011fuzhan","family":"Selvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadettin","family":"K\u0131l\u0131\u00e7kap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz Can","family":"G\u00fcven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabin G\u00f6kta\u015f","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teoman","family":"Sakalar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metin","family":"Pehlivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Keskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ol\u00e7un \u00dcmit","family":"\u00dcnal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Menek\u015fe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engin","family":"Kut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyyup","family":"\u00c7avdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem Ayd\u0131n","family":"\u0130sak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130smail","family":"Ert\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Haf\u0131zo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Ayhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurg\u00fcl","family":"Ya\u015far","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seval","family":"Orman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice Aso\u011flu","family":"R\u00fczgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Re\u015fit","family":"Akyel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mert","family":"Ba\u015faran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayhan","family":"Ert\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Mustafa","family":"Atc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"\u00c7elik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"29276_CR1","doi-asserted-by":"publisher","first-page":"937112","DOI":"10.3389\/fped.2022.937112","volume":"10","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y., Wang, Y., Wang, H., Wen, C. & Wu, X. Alveolar soft part sarcoma in childhood and adolescence: report of three cases and review of literature. Front. Pediatr. 10, 937112 (2022).","journal-title":"Front. Pediatr."},{"issue":"11","key":"29276_CR2","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1093\/jjco\/hyad102","volume":"53","author":"T Fujiwara","year":"2023","unstructured":"Fujiwara, T. et al. Advances in treatment of alveolar soft part sarcoma: an updated review. Jpn J. Clin. Oncol. 53 (11), 1009\u20131018 (2023).","journal-title":"Jpn J. Clin. Oncol."},{"issue":"22","key":"29276_CR3","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.21037\/atm-20-6377","volume":"8","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. Target therapy for metastatic alveolar soft part sarcoma: a retrospective study with 47 cases. Ann. Transl Med. 8 (22), 1493 (2020).","journal-title":"Ann. Transl Med."},{"issue":"2","key":"29276_CR4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/jamaoncol.2018.4490","volume":"5","author":"L Paoluzzi","year":"2019","unstructured":"Paoluzzi, L. & Maki, R. G. Diagnosis, Prognosis, and treatment of alveolar Soft-Part sarcoma: A review. JAMA Oncol. 5 (2), 254\u2013260 (2019).","journal-title":"JAMA Oncol."},{"issue":"3","key":"29276_CR5","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/annonc\/mdx774","volume":"29","author":"P Sch\u00f6ffski","year":"2018","unstructured":"Sch\u00f6ffski, P. et al. Activity and safety of Crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European organization for research and treatment of cancer (EORTC) phase II trial 90101 \u2018CREATE\u2019. Ann. Oncol. 29 (3), 758\u2013765 (2018).","journal-title":"Ann. Oncol."},{"issue":"7","key":"29276_CR6","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1093\/annonc\/mdq644","volume":"22","author":"S Stacchiotti","year":"2011","unstructured":"Stacchiotti, S. et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann. Oncol. 22 (7), 1682\u20131690 (2011).","journal-title":"Ann. Oncol."},{"key":"29276_CR7","first-page":"3738562","volume":"2017","author":"Y Shido","year":"2017","unstructured":"Shido, Y. & Matsuyama, Y. Advanced alveolar soft part sarcoma treated with pazopanib over three years. Case Rep. Oncol. Med. 2017, 3738562 (2017).","journal-title":"Case Rep. Oncol. Med."},{"issue":"10","key":"29276_CR8","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2303383","volume":"389","author":"AP Chen","year":"2023","unstructured":"Chen, A. P. et al. Atezolizumab for advanced alveolar soft part sarcoma. N Engl. J. Med. 389 (10), 911\u2013921 (2023).","journal-title":"N Engl. J. Med."},{"issue":"3","key":"29276_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.5301\/tj.5000617","volume":"103","author":"P Jagodzi\u0144ska-Mucha","year":"2017","unstructured":"Jagodzi\u0144ska-Mucha, P. et al. Long-term results of therapy with Sunitinib in metastatic alveolar soft part sarcoma. Tumori 103 (3), 231\u2013235 (2017).","journal-title":"Tumori"},{"issue":"2","key":"29276_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11912-007-0007-2","volume":"9","author":"G Sonpavde","year":"2007","unstructured":"Sonpavde, G. & Hutson, T. E. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr. Oncol. Rep. 9 (2), 115\u2013119 (2007).","journal-title":"Curr. Oncol. Rep."},{"issue":"9829","key":"29276_CR11","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT van der Graaf","year":"2012","unstructured":"van der Graaf, W. T. et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379 (9829), 1879\u20131886 (2012).","journal-title":"Lancet"},{"key":"29276_CR12","doi-asserted-by":"publisher","first-page":"6755","DOI":"10.2147\/CMAR.S323499","volume":"13","author":"B Alshamsan","year":"2021","unstructured":"Alshamsan, B. et al. Real-World outcome and prognostic factors of pazopanib in advanced soft tissue sarcoma. Cancer Manag Res. 13, 6755\u20136766 (2021).","journal-title":"Cancer Manag Res."},{"issue":"1","key":"29276_CR13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1634\/theoncologist.2017-0161","volume":"23","author":"S Stacchiotti","year":"2018","unstructured":"Stacchiotti, S. et al. Activity of pazopanib and trabectedin in advanced alveolar soft part sarcoma. Oncologist 23 (1), 62\u201370 (2018).","journal-title":"Oncologist"},{"key":"29276_CR14","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3332\/ecancer.2024.1813","volume":"18","author":"S Fernandes","year":"2024","unstructured":"Fernandes, S. et al. Real world outcomes in alveolar soft part sarcomas: experience with an ultra-rare sarcoma from a tertiary care centre in North India. Ecancermedicalscience 18, 1813 (2024).","journal-title":"Ecancermedicalscience"},{"issue":"4","key":"29276_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s00432-025-06208-8","volume":"151","author":"A Burkhard-Meier","year":"2025","unstructured":"Burkhard-Meier, A. et al. First-line pazopanib in patients with metastatic epithelioid hemangioendothelioma: a retrospective single-center analysis. J. Cancer Res. Clin. Oncol. 151 (4), 150 (2025).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"29276_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2340\/1651-226X.2025.42333","volume":"64","author":"BHG Van Riet","year":"2025","unstructured":"Van Riet, B. H. G. et al. Long-term survival of participants in the PASART-1 and PASART-2 trials of neo-adjuvant pazopanib and radiotherapy in soft tissue sarcoma. Acta Oncol. 64, 69\u201377 (2025).","journal-title":"Acta Oncol."},{"issue":"2","key":"29276_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001561","volume":"8","author":"J Martin-Broto","year":"2020","unstructured":"Martin-Broto, J. et al. Nivolumab and Sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib\/II trial. J. Immunother Cancer. 8(2), e001561 (2020).","journal-title":"J. Immunother Cancer."},{"issue":"4","key":"29276_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00280-023-04615-7","volume":"93","author":"K Westerdijk","year":"2024","unstructured":"Westerdijk, K. et al. Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients. Cancer Chemother. Pharmacol. 93 (4), 353\u2013364 (2024).","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29276-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29276-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29276-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T15:44:55Z","timestamp":1766072695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29276-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["29276"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-29276-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"6 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the local ethics committee (identifier: E-48670771-514.10). Due to the retrospective nature of the study, waived the need of obtaining informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"44124"}}